Combining AI and computational chemistry, we developed a series of innovative methods to address challenging drug discovery and design tasks, including molecular structure generation, binding affinity prediction, and key drug property predictions. Based on these AI-empowered capabilities, we are working with industry partners in the one-stop drug discovery of small molecules and macromolecule services, to improve research efficiency, reduce costs, and increase the overall success rate of innovative therapeutics in R&D.
Named as one of the most promising private med-tech companies in the industry
Expanding the tried-and-true "AI drug discovery + novel organoid disease models" paradigm to new cancer drug pipeline collaboration
The partnership will leverage XtalPi’s highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.